

Modupe Idowu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1706294/publications.pdf>

Version: 2024-02-01

14
papers

160
citations

1478505

6
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

240
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. <i>Scientific Reports</i> , 2017, 7, 15281.	3.3	47
2	Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activity. <i>Blood</i> , 2015, 125, 1643-1652.	1.4	44
3	Atypical thrombotic thrombocytopenic purpura in a middle-aged woman who presented with a recurrent stroke. <i>American Journal of Hematology</i> , 2013, 88, 237-239.	4.1	19
4	Epstein-Barr Virus-Related Hemophagocytic Lymphohistiocytosis: Hematologic Emergency in the Critical Care Setting. <i>Case Reports in Hematology</i> , 2015, 2015, 1-6.	0.4	13
5	Isolated Mesenteric CD20-Positive Myeloid Sarcoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e217-e220.	0.4	10
6	Atypical Thrombotic Thrombocytopenic Purpura Presenting as Stroke. <i>Case Reports in Hematology</i> , 2019, 2019, 1-4.	0.4	8
7	Risk and protective factors for severe COVID-19 infection in a cohort of patients with sickle cell disease. <i>Journal of Investigative Medicine</i> , 2022, 70, 1243-1246.	1.6	6
8	A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.4	5
9	Patient perception of voxelotor treatment benefit in sickle cell disease. <i>Journal of Investigative Medicine</i> , 2022, 70, 1316-1319.	1.6	4
10	Disseminated cytomegalovirus-associated hemophagocytic lymphohistiocytosis in an elderly patient. <i>Blood Research</i> , 2016, 51, 288.	1.3	2
11	Feigning Acute Intermittent Porphyria. <i>Case Reports in Psychiatry</i> , 2014, 2014, 1-4.	0.5	1
12	Patient Perception of Oxbraya™ Treatment Benefit. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
13	Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. <i>Blood</i> , 2016, 128, 2474-2474.	1.4	0
14	Depression, Anxiety and Pain Medication Utilization in Adult Patients with Sickle Cell Disease. <i>Blood</i> , 2020, 136, 1-1.	1.4	0